Immune expression and inhibition of heat shock protein 90 in uveal melanoma

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 847-855

  Faingold, Dana ^a   Marshall, Jean Claude ^a   Antecka, Emilia ^a   Di Cesare, Sebastian ^a   Odashiro, Alexandre N ^a   Bakalian, Silvin ^a   Fernandes, Bruno F ^a   Burnier Jr , Miguel N ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN DEPENDENT KINASE 4; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE B; SULFORHODAMINE B; TANESPIMYCIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INHIBITION KINETICS; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UVEA TUMOR; WESTERN BLOTTING;

BENZOQUINONES; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LACTAMS, MACROCYCLIC; MELANOMA; UVEAL NEOPLASMS;

EID: 38949105894     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0926     Document Type: Article

References (48)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239-51.
2. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 2006;46:151-66.
3. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3-24.
4. Buchner J. Hsp90 & Co. - a holding for folding. Trends Biochem Sci 1999;24:136-41.
5. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
6. Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004;3:1530-6.
7. Niikura Y, Ohta S, Vandenbeldt KJ, Abdulle R, McEwen BF, Kitagawa K. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation. Oncogene 2006;25:4133-46.
8. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-82.
9. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006;12:6087-93.
10. Marshall JC, Caissie AL, Callejo SA, Antecka E, Burnier MN, Jr. Cell proliferation profile of five human uveal melanoma cell lines of different metastatic potential. Pathobiology 2004;71:241-5.
11. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-9.
12. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors in metastasis. Hum Pathol 1982;13:123-32.
13. Becker B, Multhoff G, Farkas B, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004;13:27-32.
14. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
15. Cappello F, David S, Ardizzone N, et al. Expression of heat shock proteins hsp10, hsp27, hsp60, hsp70, and hsp90 in urothelial carcinoma of urinary bladder. J Can Mol 2006;2:73-7.
16. DeWaard-Siebinga I, Blom DJ, Griffioen M, et al. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 1995;62:155-61.
17. Albert DM, Ruzzo MA, McLaughlin MA, Robinson NL, Craft JL, Epstein J. Establishment of cell lines of uveal melanoma. Methodology and characteristics. Invest Ophthalmol Vis Sci 1984;25:1284-99.
18. Di Cesare S, Marshall JC, Logan P, et al. Expression and migratory analysis of 5 human uveal melanoma cell lines for CXCL12, CXCL8, CXCL1, and HGF. J Carcinog 2007;6:2.
19. Woodward JK, Elshaw SR, Murray AK, et al. Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1α and TGF-β. Invest Ophthalmol Vis Sci 2002;43:3144-52.
20. Banerji U, O'Donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61.
21. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
22. Hsu PL, Hsu SM. Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease. Cancer Res 1998;58:5507-13.
23. Yano M, Naito Z, Tanaka S, Asano G. Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 1996;87:908-15.
24. Pick E, Kluger Y, Giltnane JM, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res 2007;67:2932-7.
25. Zuo DS, Dai J, Bo AH, Fan J, Xiao XY. Significance of expression of heat shock protein90α in human gastric cancer. World J Gastroenterol 2003;9:2616-8.
26. Nanbu K, Konishi I, Mandai M, et al. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev 1998;22:549-55.
27. Elpek GO, Karaveli S, Simsek T, Keles N, Aksoy NH. Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries. APMIS 2003;111:523-30.
28. Vanmuylder N, Evrard L, Daelemans P, Van Reck J, Dourov N. [Expression of heat shock proteins in salivary gland tumors. Immunohistochemical study of HSP27, HSP70, HSP90, and HSP110: apropos of 50 cases]. Ann Pathol 2000;20:190-5.
29. Missotten GS, Journee-de Korver JG, de Wolff-Rouendaal D, Keunen JE, Schlingemann RO, Jager MJ. Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:3059-65.
30. McLean IW, Saraiva VS, Burnier MN Jr. Pathological and prognostic features of uveal melanomas. Can J Ophthalmol 2004;39:343-50.
31. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007;81:15-27.
32. Eustace BK, Jay DG. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004;3:1098-100.
33. Ehlers JP, Harbour JW. Molecular pathobiology of uveal melanoma. Int Ophthalmol Clin 2006;46:167-80.
34. 1-S phase transition in uveal melanoma and retinoblastoma. Br J Ophthalmol 1998;82:961-70.
35. Teng SC, Chen YY, Su YN, et al. Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J Biol Chem 2004;279:14649-55.
36. Neckers L, Lee YS. Cancer: the rules of attraction. Nature 2003;425:357-9.
37. Burger AM, Fiebig HH, Stinson SF, Sausville EA.17-(Allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs 2004;15:377-87.
38. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17- demethoxygeldanamycin in Hodgkin's lymphoma cells downregulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-90.
39. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway inhuman cancer. Nat Rev Cancer 2002;2:489-501.
40. Saraiva VS, Caissie AL, Segal L, Edelstein C, Burnier MN, Jr. Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res 2005;15:245-50.
41. Fujiwara H, Yamakuni T, Ueno M, et al. IC101 induces apoptosis by Akt dephosphorylation via an inhibition of heat shock protein 90-ATP binding activity accompanied by preventing the interaction with Akt in L1210 cells. J Pharmacol Exp Ther 2004;310:1288-95.
42. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
43. Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998;273:29864-72.
44. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996;10:1491-502.
45. Li H, Niederkorn JY, Neelam S, Alizadeh H. Resistance and susceptibility of human uveal melanoma cells to TRAIL-induced apoptosis. Arch Ophthalmol 2005;123:654-61.
46. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003-9.
47. Pandey P, Saleh A, Nakazawa A, et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000;19:4310-22.
48. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function downregulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.